Skip to content

Horizon BCBS

Does Horizon BCBS cover Zepbound?

It depends on your benefits. Horizon BCBS covers Zepbound for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review June 5, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Obesity must NOT be restricted from coverage under the patient's benefit

Qualification pathways

You can qualify through any one of these.

Adult weight management (Zepbound)

All of:

  • Obesity is NOT restricted from coverage under the patient's benefit
  • Patient does NOT have Type 2 diabetes
  • Patient is new to therapy, new to Prime, or attempting a repeat weight loss course of therapy
  • Patient is an adult (> 18 years of age)
  • BMI ≥ 35 kg/m2 with at least one comorbidity (e.g., hypertension, OSA, CVD, dyslipidemia)
  • Weight loss regimen of low-calorie diet, increased physical activity, and behavioral modifications for minimum 6 months (documentation required within last 6 months)
  • Baseline weight and BMI obtained during in-office visit within last 30 days
  • Active participation in in-person, digital, or telehealth weight management program
  • Patient starting therapy OR has achieved and maintained weight loss ≥ 5% from baseline
  • Will NOT use in combination with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to requested agent
  • Currently on low-calorie diet, increased physical activity, and behavioral modifications

Plus any one of:

  • Patient has NOT tried a targeted weight loss agent (e.g., Saxenda, Wegovy, Zepbound) in the past 12 months
  • Patient has tried a targeted weight loss agent in the past 12 months AND prescriber anticipates success with repeating therapy
  • Inadequate response to 3-month trial of liraglutide (Saxenda generic) not expected to occur with Zepbound
  • Intolerance or hypersensitivity to liraglutide (Saxenda generic) not expected to occur with Zepbound
  • FDA labeled contraindication to liraglutide (Saxenda generic) not expected to occur with Zepbound

Documentation to bring

  • Documentation that obesity is NOT restricted from coverage under patient's benefit
  • Documentation confirming patient does NOT have Type 2 diabetes
  • Baseline weight and BMI from in-office visit within the last 30 days
  • Documentation of active participation in lifestyle changes within last 6 months (e.g., food diary, exercise log, step counter report, gym attendance log, fitness tracker printout)
  • Medical records confirming active participation in in-person, digital, or telehealth weight management program
  • Medical records supporting prior liraglutide (Saxenda generic) trial (inadequate response, intolerance, or contraindication) OR documentation that patient has not tried a targeted weight loss agent in past 12 months OR documentation supporting repeat therapy with prescriber anticipation of success
  • MedWatch form if intolerance/hypersensitivity to liraglutide is the reason for step-through

Quantity limits

  • 2.5mg — 4 vials or 4 pens per 180 days (84-day)
  • 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 vials or 4 pens per 28 days

Approval and renewal

  • Initial approval: 3 months
  • Renewal: every 6 months
  • Renewal: Adult: weight loss ≥ 5% from baseline OR weight loss ≥ 1 lb/week from baseline; AND baseline BMI ≥ 35 and current BMI ≥ 35 (measured within last 30 days). Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required. Note: no pediatric (12-17) pathway specified for Zepbound in the criteria.

Not covered when

  • Type 2 diabetes (T2DM patients excluded from weight loss indication)
  • Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Concomitant use with another GLP-1 receptor agonist
  • Any FDA labeled contraindications to the requested agent

Policy note: Zepbound 2.5mg has a quantity limit of 4 vials/pens per 180 days; all other strengths are 4 vials/pens per 28 days. Quantity limit criteria allow exceptions for Zepbound 2.5mg used for maintenance therapy if patient cannot use higher strength maintenance dose and has achieved weight loss on lower strength. Initial approval duration 3 months for obesity indication. Renewal approval is 6 months. Step-therapy requires prior liraglutide (Saxenda generic) trial or documented intolerance/contraindication. No pediatric pathway is explicitly described for Zepbound in the weight loss criteria (unlike Saxenda and Wegovy). Adult-only weight loss criteria implied by the qualification pathway.

verified June 5, 2026 · source: GLP-1 For Non Diabetic Use · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (1 plan type)

Applies to Employer plans.

Covered with requirements

Qualification pathways

You can qualify through any one of these.

OSA with obesity (Zepbound)

All of:

  • Diagnosis of obstructive sleep apnea (OSA) (medical records required)
  • Polysomnography (PSG) or home sleep apnea test performed (sleep study required)
  • AHI ≥ 15 events/hour from baseline (prior to initiation of pharmacotherapy) (sleep study required)
  • Requested agent is Zepbound
  • BMI ≥ 30 kg/m2 (medical records required)
  • Will NOT use in combination with another weight loss agent
  • Will NOT use in combination with another GLP-1 receptor agonist
  • No FDA labeled contraindications to requested agent
  • Currently on low-calorie diet, increased physical activity, and behavioral modifications

Documentation to bring

  • Medical records confirming diagnosis of obstructive sleep apnea (OSA)
  • Sleep study results (polysomnography or home sleep apnea test) showing AHI ≥ 15 events/hour at baseline
  • Medical records confirming BMI ≥ 30 kg/m2

Quantity limits

  • 2.5mg — 4 vials or 4 pens per 180 days (84-day)
  • 5mg, 7.5mg, 10mg, 12.5mg, 15mg — 4 vials or 4 pens per 28 days

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 6 months
  • Renewal: Patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). OSA diagnosis and AHI/BMI requirements are NOT re-verified at renewal — only clinical benefit confirmation is required.

Not covered when

  • Concomitant use with another weight loss agent (e.g., Contrave, phentermine, Qsymia, Xenical)
  • Concomitant use with another GLP-1 receptor agonist
  • Any FDA labeled contraindications to the requested agent

Policy note: PAP therapy trial is NOT required prior to approval — the policy does not mandate a prior PAP/CPAP trial. Both patients currently on PAP and those not on PAP are eligible (consistent with SURMOUNT-OSA trial design referenced in the document). AHI ≥ 15 events/hour corresponds to moderate-to-severe OSA. Initial approval is 6 months (non-obesity indication). Renewal is 6 months with clinical benefit required (reduction in AHI or decrease in Epworth Sleepiness Scale).

verified June 5, 2026 · source: GLP-1 For Non Diabetic Use · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Horizon BCBS has separate Zepbound policies that don't depend on that benefit:

Questions people ask
Does Horizon BCBS cover Zepbound?
It depends on your benefits. Horizon BCBS covers Zepbound for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Zepbound approval last with Horizon BCBS?
Weight Loss — Applies to Employer plans. Initial approval: 3 months. Renewal: every 6 months. Obstructive Sleep Apnea (OSA) — Applies to Employer plans. Initial approval: 6 months. Renewal: every 6 months.
What does Horizon BCBS require to renew Zepbound?
Weight Loss — Applies to Employer plans. Adult: weight loss ≥ 5% from baseline OR weight loss ≥ 1 lb/week from baseline; AND baseline BMI ≥ 35 and current BMI ≥ 35 (measured within last 30 days). Failed efficacy precludes future coverage of same drug. Obesity benefit restriction and T2DM exclusion are re-verified at renewal. BMI must be obtained during in-office visit within last 30 days. Continued active participation in weight management program required. Note: no pediatric (12-17) pathway specified for Zepbound in the criteria. Obstructive Sleep Apnea (OSA) — Applies to Employer plans. Patient must have had clinical benefit with the requested agent (e.g., reduction in AHI, decrease in Epworth Sleepiness Scale). OSA diagnosis and AHI/BMI requirements are NOT re-verified at renewal — only clinical benefit confirmation is required.
How current is this information?
The oldest review date among the policies on this page is June 5, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Horizon BCBS: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: BCBS Alabama, BCBS Arizona, BCBS Arkansas, BCBS Massachusetts, BCBS Michigan, BCBS Minnesota, BCBS Nebraska, BCBS North Carolina

All insurance plans · All medications

Summary of Horizon BCBS's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.